Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part ...

AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares down more than 10% in ...

AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics. The program also includes an ...

AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a ...